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Dysregulation of iron metabolism has been observed in patients with neurodegenerative diseases (NDs). Utilization of several
importers and exporters for iron transport in brain cells helps maintain iron homeostasis. Dysregulation of iron homeostasis leads
to the production of neurotoxic substances and reactive oxygen species, resulting in iron-induced oxidative stress. In Alzheimer’s
disease (AD) and Parkinson’s disease (PD), circumstantial evidence has shown that dysregulation of brain iron homeostasis leads
to abnormal iron accumulation. Several genetic studies have revealed mutations in genes associated with increased iron uptake,
increased oxidative stress, and an altered inﬂammatory response in amyotrophic lateral sclerosis (ALS). Here, we review the recent
ﬁndings on brain iron metabolism in common NDs, such as AD, PD, and ALS. We also summarize the conventional and novel
types of iron chelators, which can successfully decrease excess iron accumulation in brain lesions. For example, iron-chelating
drugs have neuroprotective eﬀects, preventing neural apoptosis, and activate cellular protective pathways against oxidative stress.
Glial cells also protect neurons by secreting antioxidants and antiapoptotic substances. These new ﬁndings of experimental and
clinical studies may provide a scientiﬁc foundation for advances in drug development for NDs.
1.Introduction
Iron (Fe) is an essential but a possibly hazardous micronu-
trient for animals, plants, humans, and microorganisms.
Mammalian cells require iron for fundamental biochemical
activities such as oxygen transport, energy metabolism, and
DNAsynthesis.Inhumans,ironstoresaremainlydistributed
among reticulocytes, macrophages, and the liver [1], and the
balance between iron absorption and output is controlled by
the intestine [2].
Dietary nonheme iron is generally found in the ferric
(Fe3+) state, and it requires to be reduced to the ferrous
(Fe2+) state for absorption. This reduction from Fe3+ to
Fe2+ is mediated by a ferric reductase [3, 4] called duo-
denal cytochrome b [5, 6], which resides on the luminal
surface of intestinal absorptive cells. Once reduced, Fe2+ is
transported across the apical membrane of enterocytes by
the divalent metal transporter 1 (DMT1) [7]. Internalized
Fe2+ is processed by enterocytes and eventually exported
across the basolateral membrane into the bloodstream via
the solute carrier and Fe2+ transporter, ferroportin 1 (FPN1)
[8]. Fe2+ is then oxidized to Fe3+ via the membrane-
bound ferroxidase, hephaestin, which physically interacts
with FPN, and its plasma homologue, ceruloplasmin (CP)
[9]. The FPN1-mediated eﬄux of Fe2+ from enterocytes into
the plasma is critical for systemic iron homeostasis. This
process is negatively regulated by hepcidin, a liver-derived
peptide hormone that binds to FPN1 and promotes its
phosphorylation,internalization,andlysosomaldegradation
[10]. Iron is delivered to tissues by circulating transferrin
(Tf), a transporter that captures iron released in plasma
mainly from intestinal enterocytes or reticuloendothelial2 Advances in Pharmacological Sciences
macrophages. Speciﬁcally, dietary iron excreted from ente-
rocytes and reticulocytes binds to Tf in a process catalyzed
by CP and is delivered to all organs and tissues, including the
brain cells. Circulating iron-laden Tf binds with high aﬃnity
to the Tf receptor 1 (TfRl) on the cell surface, resulting in
endocytosis and internalization of the TfR-Tf-iron complex
in the cell. A proton pump promotes acidiﬁcation of the
endosome,triggeringthereleaseofFe3+ fromTfthatremains
bound to TfR1. Fe3+ is reduced to Fe2+, which is transported
across the endosomal membrane by DMT1 to the cytosol
where it can be sequestered by ferritin. Iron can also be
directly transported to the mitochondria where it is utilized
for energy synthesis or formation of iron sulfur clusters for
iron sensing. In cells, the best-characterized iron-sensing
mechanism is the result of posttranscriptional regulation of
mRNA. Sequences of mRNA called iron-responsive elements
(IREs) are contained within mRNA sequences that encode
ferritin and TfR. IRE-binding proteins (IRE-BP1 or IRE-
BP2) bind to these mRNA sequences and regulate post-
transcriptional expression of these iron metabolism-related
mRNAs. Speciﬁcally, when cellular iron levels are low, IRE-
BP exists as a 3Fe-4S iron sulfur cluster and binds to IREs
located in the 5  and 3  untranslated regions (UTRs) of
ferritin and TfR mRNA, respectively. This binding inhibits
translationoftheironstorageprotein,ferritin.Whencellular
iron levels are low, IRE-BP containing the 3Fe-4S cluster
also stabilizes TfR mRNA, causing an increase in the mRNA
translation of TfR proteins. Once generated, these proteins
are embedded in the cell’s plasma membrane to promote
cellular iron uptake. When cellular iron levels are high,
IRE-BP changes to the alternate 4Fe-4S cluster; in this
form, its mRNA-binding activity is repressed, and IRE-BP
is released from IRE. Without the binding of IRE-BP (4Fe-
4S), ferritin mRNA undergoes translation. TfR mRNA is
rapidly degraded, decreasing translation, which results in
the production of fewer TfR proteins. Other known genes
that encode IREs in their mRNA 5 -UTRs include DMT1,
5-aminolevulinic acid synthetase, hypoxia-inducible factor
2a (HIF-2a), and amyloid precursor protein (APP). Recent
studies have shown that IRE-BP2 is degraded by SKP1-
CUL1-FBXL5 ubiquitin ligase protein complex in HEK293
cells [11, 12]. This complex directly senses iron level through
FBXL5, a member of the F-box family of adaptor proteins
that has iron-binding hemerythrin-like domains at its N
terminus. Thus, iron homeostasis also involves a proteolytic
pathway that couples with IRE-BP2-dependent translational
r e g u l a t i o ni nc e l l s .
2. IronMetabolisminthe Brain
Iron uptake in the brain is mediated by the expression of TfR
ontheluminalendothelialsurfaceintheblood-brainbarrier.
As shown in Figure 1, TfR binds to Tf-bound Fe3+ derived
from diet and excreted from enterocytes and reticulocytes.
This is followed by internalization of the Tf-TfR complex
into endosomes. Acidiﬁcation of the endosome facilitates the
release of Fe3+, which is reduced by a ferric reductase to
Fe2+ [1, 3, 13]. Once Fe2+ is transported into the cytosol of
endothelialcellsbyendosomalDMT1[13],itisexportedinto
CNSbyFPN1.AfterFe2+ release,TfRisrecycledtobindiron-
laden Tf in the blood.
Neurons express TfR, DMT1, APP, FPN1, and ferritin as
iron regulators but do not express CP. Therefore, neurons
take up both Tf-bound and non-Tf-bound iron (NTBI).
Interestingly, a novel iron-regulatory signaling cascade in
neurons called the N-methyl D-aspartate (NMDA) receptor-
nitric oxide (NO) signaling pathway physiologically induces
iron uptake via glutamine-NMDA activation [14]. Down-
stream of this cascade, DMT1 physically interacts with
peripheral benzodiazepine receptor-associated protein 7,
which plays a role in signaling with S-nitrosylation of
Dexras1 from the NMDA receptor at both the endosome
and plasma membrane. Moreover, Cheah et al. showed that
overactivation of NMDA receptors leads to neurotoxicity,
which is prevented by iron chelation.
Astrocytes speciﬁcally express CP [15] and oxidize Fe2+
to Fe3+ following binding to Tf. Although astrocytes are
the primary cells in CNS that express Tf, oligodendrocytes
also express Tf [16]. In cases where Tf is highly saturated
by iron, NTB1 may be present in signiﬁcant amounts and
may function as an important iron source for cells such
as oligodendrocytes, which do not express much TfR1.
NTBI binds to citrate [17] or ATP derived from astrocytes
to function as a source of iron for oligodendrocytes and
astrocytes. Microglia express DMT1, APP, and ferritin,
suggesting that glial cells assist neurons in maintaining iron
homeostasis in the brain environment. Once abnormal iron
homeostasisinducesoxidativestressinthebrain,neuronsare
exclusively damaged by the resulting neurotoxicity, leading
to the development of neurodegenerative diseases (NDs).
However, the glial cells with diverse functions may regulate
iron metabolism to protect the normal function of neurons.
Elucidation of the mechanisms underlying the interaction
between neurons and glial cells in the brain may lead to a
better understanding of iron homeostasis within the cell, and
its dysregulation in NDs.
3. Iron Metabolism and
Neurodegenerative Diseases
3.1. Iron Metabolism in Alzheimer’s Disease. Alzheimer’s
disease (AD) is a slowly progressing disease of the brain
characterized by impairment of memory and disturbances
in reasoning, planning, language, and perception. The main
risk factor for AD is advanced age. Classic pathological
features of AD are aggregates of insoluble amyloid beta-
protein (Ab), and neuroﬁbrillary tangles (NFTs) consisting
of precipitates or aggregates of hyperphosphorylated tau
protein. Fe3+ binds to hyperphosphorylated tau protein and
is reduced to Fe2+, which induces NFT production [18].
Redox-active iron (Fe2+/Fe3+ complexes) is deposited near
the Ab plaques and NFT in the cortex of AD brains [19]. Ab
triggers neuritic degradation in both neurites and synapses
[20, 21]. APP, a type I transmembrane protein and a well-
known precursor protein of Ab, is ubiquitously localized in
neuron, glial, and the other cells [22, 23]( Figure 1).
The presence of IRE in APP mRNA suggests an associ-
ation between iron metabolism and AD [24]. APP IRE isAdvances in Pharmacological Sciences 3
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Figure 1: Iron metabolism in the brain. Transferrin (Tf) bound to ferric iron (Fe3+) is taken up by the Tf receptor (TfR) in the luminal
membrane of endothelial cells, and Fe3+-laden Tf and TfR complex are internalized into endosomes. Fe3+-bound Tf is reduced by duodenal
cytochrome b to ferrous iron (Fe2+). Fe2+ may be transported to the cytosol by the divalent metal transporter l (DMT1) in the endosomal
membrane and exported into the extracellular ﬂuid by ferroportin l (FPN1). FPN1 interacts with the amyloid precursor protein (APP),
which may function as a ferroxidase at the plasma membrane of neurons, microglia, and astrocytes. After Fe2+ release, Tf is recycled to bind
to Fe3+ in the blood. Ceruloplasmin (CP) on the membrane of astrocytes oxidizes Fe2+ to Fe3+ to bind for subsequent binding to Tf. Neurons
take up Tf-bound and non-Tf-bound iron (NTBI). NTBI may also bind to citrate and ATP derived from astrocytes to function as a source
of iron for oligodendrocytes and astrocytes. Oligodendrocytes synthesize Tf, which play a role in intracellular transport. The cytosolic iron
storage protein ferritin traps and stores NTBI in the brain cells.
homologous with the canonical IRE RNA stem loop that
binds IRE-BP1/IRE-BP2 in order to regulate intracellular
iron homoeostasis by modulating ferritin mRNA translation
and TfR mRNA stability. APP IRE interacts with IRE-
BP1, whereas the heavy subunit of ferritin (H-ferritin)
IRE binds to IRE-BP2 in neural cell lines, human brain
cortex tissue, and human blood lysates [25]. Both IRE-
BPs are implicated in iron regulation in the brain; IRE-
BP1 binds to APP IRE, [26] and IRE-BP2 upregulates APP
gene expression in the hippocampus of IRE-BP2 mice (−/−)
[27]. Recently, Duce et al. showed that a motif within
the E2 domain of APP that is homologous to H-ferritin
possesses ferroxidase activity. In addition, APP interacts with
FPN and assists in iron eﬄux to extracellular ﬂuid [23].
Moreover, alpha-cleavage of APP is regulated by iron loading
in vitro, suggesting that iron-mediated oxidative stress causes
APP misregulation [28]. However, it is unclear if APP
misregulation is the underlying cause of AD and other NDs.
Furthermore, APP and CP mRNAs are translationally reg-
ulated by proinﬂammatory cytokines: interleukin-1 (IL-1)
and interferon gamma, respectively [29, 30], indicating
an association between AD and inﬂammatory responses
within the brain that are primarily performed by activated
microglia. Thus, examining the eﬀect of iron on the interac-
tions between neurons and microglial cells may provide us
with the physiological causes underlying AD pathogenesis.
3.2. Iron Metabolism in Parkinson’s Disease. Parkinson’s dis-
ease (PD) is an ND caused by dopaminergic neuronal cell
death in the substantia nigra (SN). The main symptoms of
PD patients are tremors in the hands and feet, bradykinesia,
rigidity, and postural instability. The neuropathological
features of PD are intracytoplasmic inclusions in SN, known
as Lewy bodies, which are widely distributed through-
out paralimbic and neocortical regions. Phosphorylated a-
synuclein is the main component of Lewy bodies. A decrease
in the number of neurons in SN leads to an increase
in acetylcholine levels in the striatum, resulting in the
collapse of normal homeostasis. Iron deposition has been
found in dopaminergic neurons within SN [31–33]. SN also
synthesizes neuromelanin, which is an insoluble pigment
derived from cytosolic catechols present in the granule form.4 Advances in Pharmacological Sciences
Neuromelanin is associated with iron storage and binds
iron-forming stable complexes to sequester large amounts
of iron in dopaminergic neurons, resulting in elevated iron
levels. According to progression of aging as a risk factor,
melanin pigments decrease in SN. Thus, iron chelation and
sequestration are eﬀective to protect neurons. Excess iron
in dopaminergic neurons can accelerate toxic a-synuclein
ﬁbril formation, leading to cellular dysfunction [34].Ferritin
and neuromelanin may contribute to neuroprotection [35],
since free cytosolic iron can trigger oxidative stress and
promotea-synucleindepositioninLewybodies[24,36].Iron
chelation and overexpression of iron-sequestering ferritin
have protective roles in animal PD models [24].
Ar e c e n tin vitro study reported that upregulation of
DMT1 without IRE induced by L-3, 4-dihydroxyphenylala-
nine (L-DOPA), and the resulting increase in DMT1-IRE-
mediated iron inﬂux play a key role in L-DOPA-induced
neurotoxicity in cortical neurons [37]. More importantly,
elevated expression of a DMT1 isoform has been found
in SN of PD patients [38], which may be associated with
iron accumulation. Similarly, in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated mice, a PD model, increased
DMT1 expression was found in the ventral mesencephalon,
followed by corresponding iron deposition and dopamin-
ergic cell loss. Thus, DMT1 plays an instrumental role in
iron accumulation and subsequent oxidative stress-mediated
cell damage. Neurons and glial cells appear to export iron
via a GPI-anchored form of CP. Quite recently, Jin et al.
reported that a decrease in serum CP levels may speciﬁcally
promote iron deposition in SN of PD patients [39]. Genetic
andpharmacologicalexperimentshaveproventhatchelation
of excess iron may be an eﬀective therapy for PD [40].
These ﬁndings have led to the development of therapeutic
iron chelators for the treatment of NDs (see Section 4.“ I r o n
Chelation Therapy for Neurodegenerative Diseases”).
3.3. Iron Metabolism in Amyotrophic LateralSclerosis. Similar
to AD and PD, excess iron levels have also been observed
in the central nervous system (CNS) of amyotrophic lateral
sclerosis (ALS) patients [41]. Abnormal iron levels can cause
inﬂammation, microglia activation, and oxidative damage
in the brain tissue, and this is further supported by reports
that show altered expression of several iron regulators (i.e.,
TfR1, DMT1, FPN1, H-ferritin, mitochondrial ferritin, and
IRE-BP1) in ALS [42]. However, abnormalities of other iron
f a c t o r ss u c ha sT f R 2 ,N M ,C P ,a n dT a uh a v en e v e rb e e n
reported in ALS, indicating that the ALS pathophysiology
involves mechanisms of iron dysregulation diﬀerent from
those of other NDs. One of the most frequently reported
gene mutations in ALS involves superoxide dismutase 1
(SOD1), a free radical scavenger, which was identiﬁed
in about 20% of familial ALS cases, for an overall ALS
incidence of about 2%. From our original searching results,
127 diﬀerent mutations of SOD1 gene were identiﬁed in
a total of 172 cases in the ALS database [43]. The SOD1
enzyme catalyzes the conversion of O2
− to O2 and H2O2,
and consequently dysfunctional SOD1 results in imbalance
between free radicals and ions, ultimately culminating in
increased cellular oxidative stress. The potential metabolic
consequences of this are wide ranging, aﬀecting the cellular
processes such as mitochondrial electron transport, cell
proliferation, and iron metabolism. Recent reports showed
that the human ataxia type 2 (ATXN2) gene, a polyg-
lutamine disease gene mutated in spinocerebellar ataxia
type 2 (SCA2), was associated with an increased risk for
ALS [44]. In 915 cases that were examined, 4.7% of ALS
patients showed expansion of CAG repeat sequences in the
ATXN2 gene. ATXN2 directly interacts with the 43-kDa
transactive-response- (TAR-) DNA-binding protein (TDP-
43), a protein that binds to the TAR-DNA element of human
immunodeﬁciency virus type 1 and regulates RNA splicing
[45]. Pathologically, TDP-43 is also found as cytosomal-
ubiquitinated inclusions in frontotemporal lobar dementia
(FTLD), some familial ALS, and a few sporadic cases.
When cocultured neural and spinal cord cells are exposed
to agents inducing cellular stresses such as oxidative stress
(H2O2), ER stress (thapsigargin), or proteasome inhibition
(epoxomicin), TDP-43 translocates from the nucleus to the
cytosol. This is accompanied by the inactivation of cell sur-
vival signaling pathways that involve mitogen-activated pro-
tein kinase (MAPK)/extracellular signal-regulated kinases
(ERK1/2) [46]. Together, these results suggest that cellular
stressors are the key factors associated with the dysfunction
ofATXN2andTDP-43inthepathogenesisofALS.According
totheALSmutationdatabase(https://reseq.lifesciencedb.jp),
there are additional ALS causative genes, including vesicle-
associated membrane protein-associated protein B and C
(VAMP), fusion (FUS), dynactin 1 (DCTN1), and ALS2
genes and are a total 27 ALS-related genes. While the
functional relationship between these genes and ALS is still
unclear, the results are consistent with a recently conducted
genome-wide analysis of the gene expression proﬁles of glial
cells and motor neurons in two common ALS mouse models
[47]. This study revealed that in the most signiﬁcant gene
sets, the functions of ALS-related genes are commonly asso-
ciated with protein modiﬁcation/phosphorylation, muscle
contraction regulation, and stress responses or are involved
in glial cell-related functions (immune response).
The current experimental evidences in ALS studies
indicate the importance of both response to oxidative stress
and inﬂammatory systems for pathophysiological mecha-
nism of NDs [17, 48, 49]. Interestingly, recent studies have
demonstrated that the macrophage-recruiting chemokine,
monocyte chemoattractant protein 1 (MCP-1 or CCL2),
is upregulated in the glial cells of spinal cord tissues in
SOD1G93A transgenic ALS mice [48], implicating the role
of the brain’s innate immune system and related inﬂamma-
tion in ALS pathophysiology. As one of the eﬀector cells
of brain innate immune system, microglia regulate both
oxidativestressandinﬂammatoryresponsestocytokinesand
chemokines within the nervous system and regulate iron
homeostasis[49].Consistentwiththis,wedemonstratedthat
am o d e r a t en e u r a lp r o t e c t i v ee ﬀect against excess NTBI is
seen when neurons and microglia are cocultured without
astrocytes [17], suggesting that in ALS the interaction
between neurons and microglia is fundamentally related to
responses to oxidative stress and inﬂammation.Advances in Pharmacological Sciences 5
4. Iron Chelation Therapy for
Neurodegenerative Diseases
As accumulating evidence indicates the role of iron dysregu-
lation in causing neuronal cell death in the pathophysiology
of NDs, it follows that iron chelators may be promising
agents for clinical treatment of NDs. Treatment with iron
chelators aims at removing excess iron that is the cause
of neurotoxicity in brain tissue, and currently several oral,
subcutaneous, and intraperitoneal iron-chelator drug for-
mulations are already being utilized in the clinical treatment
of NDs [50].
Desferrioxamine (DFO), a natural iron scavenger iso-
lated from Streptomyces pilosus, was developed in 1961 for
thetreatmentofhemochromatosisandwastheﬁrst-designed
iron chelation drug to be manufactured [51]. In AD and PD,
DFO chelates both aluminum and iron ions and protects
against 6-hydroxydopamine-induced damage of dopaminer-
gic neurons [52, 53]. However, treatment with DFO requires
continuous dosing due to its short circulating half-life.
Furthermore, the eﬃciency of DFO in PD has been also
limited because of its inability to penetrate the blood-brain
barrier [54]. Side eﬀects of DFO administration include
injection site reactions and retinal toxicity as reported by
Bringetal.[55].Consequently,treatmentwithDFOhasbeen
regarded to negatively aﬀect the quality of life (QOL) of ND
patients.
Deferiprone(DFPorL1)isanoralFe2+-speciﬁcchelating
agent used to treat iron accumulation in thalassaemia.
Clinical trials of treatment with L1 for Friedreich’s ataxia
(FA), a severe inherited neurological disease, demonstrated
the elimination of labile iron deposits in a speciﬁc brain
region without signiﬁcant adverse changes in hemoglobin or
plasma iron levels [56]. An additional advantage of L1 is its
cost eﬀectiveness, compared to DFO as it does not require
the same long-term continuous dosing [57]. Side eﬀects of
treatment with L1 include agranulocytosis, hepatotoxicity,
zinc deﬁciency [58], and possible Ll-induced overchelation
of iron in cells despite normal levels.
The eﬃcacy and safety of several combinations of iron
chelation therapies has also been examined in recent clinical
studies, which aimed to primarily improve the QOL of
patients. Indeed, previous reports showed that combina-
tion of DFO and L1 therapy was more eﬀective and
less burdensome for the β-thalassemia patient than DFO-
only therapy [59, 60]. Reported side eﬀects in this study
include neutropenia, severe gastrointestinal disfunction, and
arthropathy but did not warrant discontinuation of therapy.
Therefore, combination therapies may be considered as an
alternative to high-dose continuous conventional therapies
for treatment of NDs due to a better QOL proﬁle.
More recently, Feralex-G (FXG), a synthetic chelator,
has been developed to chelate both cellular iron (Fe3+)a n d
aluminum (Al3+)[ 61, 62]. It has also been reported that
FXG contributes to scavenging and can repress reactive-
oxygen-species- (ROS-) triggered gene expressions in vitro
[63]. Although in vivo and in vitro investigations involving
FXG will be required to completely evaluate its potential
usefulness, the therapeutic potential of FXG in the treatment
of NDs associated with iron-induced oxidative stress is
promising.
M30 [5-(N-methyl-N-propargyaminomethyl)-8-hydrox-
yquinoline]andHLA20(5-[4-propargylpiperazin-1-ylmeth-
yl]-8-hydroxyquinoline) are multifunctional iron-chelating
compounds that have been demonstrated to possess neuro-
protective activities in mice ND models [64]. These novel
drugs have the following three characteristic functions:
iron chelation, free radical capture, and inhibition of iron-
induced membrane lipid peroxidation. Their chemical struc-
tures contain the propargyl moiety of the monoamine
oxidase-B(MAO-B)inhibitordrugs,rasagiline(Azilect),and
the antioxidant iron-chelating moiety of VK28 (5-[4-(2-hy-
droxyethyl) piperazine-1-ylmethyl]-quinoline-8-ol) [65]. In
ALS and PD models, M30 increased the rate of survivability
andpreventedtheonsetofneurologicaldysfunction[66,67].
The neuroprotective eﬀect of M30 treatment involves in
hypoxia-inducible factor-1α (HIF-1α), a key stress-sensitive
transcription factor that regulates transcription of the iron-
regulatory, antioxidative, and glycolytic genes such as TfR,
heme oxygenase-1, inducible nitric oxide synthase (iNOS),
and glucose transporter-1 [64]. Mechanistically, the iron-
chelating activity of M30 and HLA20 leads to inhibition
of HIF prolyl-4-hydroxylases, an iron-dependent suppressor
of HIF-1α. This inhibition subsequently activates HIF-
1α-dependent cell survival pathways, such as mitogen-
activated protein kinase (MAPK) and protein kinase C
(PKC) pathways, accompanied by increases in growth-
promoting factor levels, speciﬁcally those of brain-derived
neurotrophic factor in the cortex and striatum, and the
glial cell-derived neurotrophic factor in the hippocampus
and spinal cord. Kupershmidt et al. also showed that in an
ALS model, neurodegeneration induced by H2O2 and the
oxynitrite generator 3-morpholino sydnonimine 1 (SIN-1)
were signiﬁcantly reduced by M30 and HLA 20 in vitro
as demonstrated by reduced DNA fragmentation related
to apoptotic cell death, when measured by enzyme-linked
immunosorbent assay (ELISA). Moreover, these compounds
selectively inhibit the activity of MAO-B, an enzyme that
catalyzes the oxidative deamination of monoamines such as
dopamine and noradrenalin, both of which are more speciﬁc
substrates for MAOs than any other monoamines in the
cerebral cortex [68]. Such monoamine metabolic reactions
ultimately result in the production of H2O2, ammonia, and
aldehydes, all of which have potentially neurotoxic eﬀects at
high levels. It follows that selectively inhibiting MAO can
contribute to neuronal protection against redox substances.
Thus, the novel iron chelator drugs, M30 and HLA20,
potentially possess multiple pharmacological properties that
culminate in antioxidative and neuronal protective eﬀects
that would help in restoring iron homeostasis in NDs.
5. FuturePerspectivesinND Therapies
Although it appears that iron dysregulation is associated
with NDs, and iron chelators are potentially eﬀective drugs
for the treatment of these diseases, the mechanisms of iron
regulation under normal and abnormal conditions or its6 Advances in Pharmacological Sciences
neuroprotective eﬀects in the brain remain unclear. The
common pathological features in NDs indicate that damage
from oxidative stressors such as iron overload, H2O2,a n d
endogenous neurotoxins primarily aﬀect neurons in the
brain. Recent clinical studies showed that iron chelators suc-
cessfully capture iron in the brain and other tissues, thereby
decreasing abnormal iron accumulation and inhibiting free
radical production. However, conventional iron chelation
therapies showed severe side eﬀects that patients could not
recover from, thereby indicating that saferand more eﬀective
drugs are required for the treatment of NDs. Combined iron
chelation therapies are considered eﬀective for the treatment
of PD and AD, and they may also be useful for the treatment
of other NDs such as ALS. Combination of an iron chelator
with an MAO inhibitor provides neuroprotective eﬀects in
thebrain,whichcouldpreventapoptosisandactivatecellular
protective pathways against oxidative stresses. However, it
is considered by some that despite the eﬀectiveness of
MAO inhibitors, products of monoamine metabolisms may
contribute to neurotoxicity. It remains unclear whether the
enzyme activity of MAOA and MAOB has cellular-, tissue-,
andorganism-speciﬁcdiﬀerences[68].Suchheterogeneityin
the activities of MAO indicates that further knowledge about
redox regulatory mechanisms in the brain is required for its
clinical application in the treatment of ND.
The brain comprises not only neurons but also glial cells,
which maintain internal brain homeostasis by supporting
neuron structures, regulating the clearance of neurotrans-
mitters, and releasing gliotransmitters. There have been
severalreportsonneuroprotectionagainstoxidativestressors
by glial cells [69, 70]. In these reports, astrocytes were shown
topreserveneuronsfromROS-andnitrogenspecies-induced
neuronal damages. Some reports indicate that microglia also
prevent NO-induced neuronal apoptosis by secreting heat-
labile and -stable neuroprotective factors in vitro [70]. How-
ever, other reports have shown that microglia cause neuronal
cell death by secreting neurotoxic substances including ROS
[71, 72]. At ﬁrst glance, these reports appear conﬂicting
as they state that microglia mediate both neuroprotection
and neuronal cell death. However, both studies make sense
when one takes into account the possibility that microglia
potentially have multiple roles, including their functions
as macrophages that regulate immune and inﬂammatory
responses. Interestingly, their immunological activities are
regulated by iron ﬂuxes mediated by hepcidin and FPN [49].
Thus, there is a high possibility that drugs for NDs aﬀect not
only neurons but also glial cells.
Currently, several in vitro studies suggest that the brain
has potential antioxidative abilities that can protect cells
against oxidative damage and maintain brain homeostasis.
However, knowledge about endogenous antioxidative mech-
anisms in the brain remains insuﬃcient to improve non-
inherited heterogeneous NDs that result from complicated
anti-/pro-oxidative molecular system dysfunctions. Thus,
clinical studies on the biological signiﬁcance of drug inter-
actions and on experimental evidence for iron-mediated
oxidative stresses in the brain are necessary. Further research
advances will aid in the development of novel, eﬀective,
molecule/cell-targeted, and safer drugs for NDs.
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